NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Operating Leases of $66000.0 for Q4 2025, down 22.35% sequentially from $85000.0 in Q3 2025, and down 67.33% YoY from $202000.0 in Q4 2024.
NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Operating Leases for 5 years, with the latest figure at $66000.0 in Q4 2025.
- Quarterly Operating Leases fell 67.33% year-over-year to $66000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $66000.0 (down 67.33% YoY) and the FY2025 annual result came in at $66000.0, down 67.33% from the prior year.
- Operating Leases declined to $66000.0 in Q4 2025 per NAMS's latest filing, from $85000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $328000.0 in Q2 2024 and troughed at $57133.9 in Q4 2022.
- A 5-year average of $144080.6 and a median of $114990.4 in 2021 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases surged 370.65% in 2024, then slumped 68.6% in 2025.
- Over 5 years, Operating Leases stood at $126980.8 in 2021, then plunged by 55.01% to $57133.9 in 2022, then increased by 21.98% to $69691.2 in 2023, then soared by 189.85% to $202000.0 in 2024, then sank by 67.33% to $66000.0 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $66000.0, $85000.0, and $103000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 137,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 266,000.00 |
| Jun 30, 2024 | 328,000.00 |
| Jun 30, 2023 | 69,691.16 |
| Dec 31, 2022 | 57,133.85 |
| Dec 31, 2021 | 126,980.78 |